Ethyl-EPA Treatment of Prodromal Patients
Sponsor
Yale University (Other)
Overall Status
Completed
CT.gov ID
NCT00634361
Collaborator
(none)
7
1
47
Study Details
Study Description
Brief Summary
This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2/Phase 3 |
Study Design
Study Type:
Interventional
Actual Enrollment
:
7 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Ethyl-EPA Treatment of Prodromal Patients
Study Start Date
:
Sep 1, 2001
Actual Primary Completion Date
:
Aug 1, 2005
Actual Study Completion Date
:
Aug 1, 2005
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: A
|
Drug: ethyl-eicosapentaenoic acid
2 mg per day
Other Names:
|
Outcome Measures
Primary Outcome Measures
- conversion to psychosis [one year]
Eligibility Criteria
Criteria
Ages Eligible for Study:
14 Years
to 35 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- meets criteria for schizophrenia prodrome
Exclusion Criteria:
- any lifetime antipsychotic treatment
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Yale University
Investigators
- Principal Investigator: Scott W Woods, MD, Yale University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Yale University
ClinicalTrials.gov Identifier:
NCT00634361
Other Study ID Numbers:
- LA01.03.0011
- NCT00237835
First Posted:
Mar 13, 2008
Last Update Posted:
May 22, 2014
Last Verified:
May 1, 2014